Eusol Biotech Co.,Ltd. (6652.TWO)

TWD 7.77

(-0.38%)

Market Cap (In TWD)

1.06 Billion

Revenue (In TWD)

-

Net Income (In TWD)

-51.61 Million

Avg. Volume

49.83 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.31-11.2
PE
-
EPS
-
Beta Value
-0.254
ISIN
TW0006652001
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Hong-Jen Chang M.D., M.P.H., M.S.
Employee Count
-
Website
https://www.eusol-biotech.com
Ipo Date
2018-08-29
Details
Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect. The company was founded in 1994 and is headquartered in Taipei, Taiwan.